Focused Alpha LLC’s AbbVie ABBV Stock Holding History

Focused Alpha LLC’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$561K	Buy	2,228 +573	+35%	+$123K	0.14%	142
2026 Q1	$360K	Sell	1,655 -90	-5%	-$20K	0.11%	181
2025 Q4	$399K	Buy	+1,745	New	+$398K	0.12%	167

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Focused Alpha LLC's ABBV Position: Q2 2026 in Review

Focused Alpha LLC increased its AbbVie (ABBV) stake by 35% in Q2 2026, buying an estimated $123K and bringing the position to 2,228 shares worth $561K. The position accounts for 0.14% of the portfolio, ranked #142.

Focused Alpha LLC first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Focused Alpha LLC held 2,228 shares of AbbVie worth $561K as of Q2 2026.
Focused Alpha LLC bought 573 AbbVie shares in Q2 2026, an estimated $123K.
AbbVie made up 0.14% of Focused Alpha LLC's portfolio in Q2 2026, its #142 holding.
Focused Alpha LLC first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Focused Alpha LLC's 13F filing for Q2 2026, filed 7 Aug 2026.